A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Exclusion Criteria

• •Active concomitant malignancies.
• •Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days prior to study start).
• •Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
• •Requiring intravenous (IV) alimentation.
• •Pregnancy or lactation.
• •Chemotherapy, anticancer immunotherapy, monoclonal antibodies or biologics within 21 days prior to first dose of study drug.
• •Anti-ErbB1 and/or ErbB2 targeted therapy or anticancer hormonal therapy within 14 days prior to first dose of study drug.
• •History of hypersensitivity to or intolerance of docetaxel.
• •Other criteria exist.